Lymphoma classification update: B-cell non-Hodgkin lymphomas.

Expert Rev Hematol

a Department of Laboratory Medicine and Pathology , Mayo Clinic, Rochester , MN , USA.

Published: May 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. A 2016 revision to the WHO classification of lymphoid neoplasms recently was reported. The present review focuses on B-cell non-Hodgkin lymphomas, the most common group of lymphomas, and summarizes recent changes most relevant to hematologists and other clinicians who care for lymphoma patients. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revision of the WHO classification particularly impact the subclassification and genetic stratification of diffuse large B-cell lymphoma and high-grade B-cell lymphomas, and reflect evolving criteria and nomenclature for indolent B-cell lymphomas and lymphoproliferative disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1318053DOI Listing

Publication Analysis

Top Keywords

lymphoma classification
12
b-cell non-hodgkin
8
non-hodgkin lymphomas
8
2016 revision
8
revision classification
8
b-cell lymphomas
8
lymphomas
7
lymphoma
5
b-cell
5
classification
5

Similar Publications

Background: The aim of this review is to present the role of intraoperative flow cytometry (IFC) in the intracranial tumor surgery. This scoping review aims to summarize current evidence on the intraoperative use of IFC in patients with intracranial tumors.

Methods: A comprehensive literature search was conducted in the Medline, Cochrane and Scopus databases up to January 21, 2025.

View Article and Find Full Text PDF

[Treatment of adult T-cell leukemia/lymphoma: past, present, and future].

Rinsho Ketsueki

September 2025

Department of Hematology and Rheumatology, Kagoshima University.

Adult T-cell leukemia/lymphoma (ATL) is a T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1). Treatment strategies have been established by classification of ATL as aggressive (acute, lymphoma, and chronic ATL with any unfavorable prognostic factors) or indolent (smoldering and chronic ATL without any unfavorable prognostic factors). The standard of care (SOC) for aggressive ATL has been dose-intensified multi-agent chemotherapy.

View Article and Find Full Text PDF

Background: Lymphoma staging plays a pivotal role in treatment planning and prognosis. Yet, it still relies on manual interpretation of PET/computed tomography (CT) images, which is time-consuming, subjective, and prone to variability. This study introduces a novel radiomics-based machine learning model for automated lymphoma staging to improve diagnostic accuracy and streamline clinical workflow.

View Article and Find Full Text PDF

Indolent B-cell lymphoma (iBCL) represents a group of mature B-cell clonal proliferative disorders that frequently involve the peripheral blood and bone marrow. In light of the fifth edition of the World Health Organization (WHO) classification of haematolymphoid tumors published in 2022, some changes have been introduced in the classification and nomenclature of certain iBCL subtypes. Accordingly, in this consensus, the disease spectrum of iBCL was reclassified based on the 2022 WHO framework.

View Article and Find Full Text PDF